Over time, Adeno-associated virus (AAV) vectors have become the leading platform for gene delivery in the potential treatment of a variety of human diseases.
Researchers and bioanalytical scientists within the gene therapy community have focused on characterizing various AAV serotypes using conventional and next-generation technologies to deliver critical quality attributes along their workflow.
In this application note, discover how AlphaLISA™ and LabChip® GXII Touch™ microfluidics-based CE technology can be used as orthogonal methodologies to detect and characterize AAV8 serotype capsid proteins.
For research use only. Not for use in diagnostic procedures.
Complementary platforms that enable multiparametric characterization of AAV capsids